Vapotherm is a technology company.
Vapotherm has raised $73.0M across 3 funding rounds.
Vapotherm has raised $73.0M in total across 3 funding rounds.
Vapotherm, Inc. is a medical technology company specializing in non-invasive high velocity therapy (HVT) devices for respiratory distress treatment across neonates, pediatrics, and adults. Its flagship products, like the Precision Flow Hi-VNI® system and HVT 2.0, deliver heated, humidified, oxygenated air via a comfortable nasal cannula, serving hospitals and clinicians worldwide by solving mask-related issues such as claustrophobia, aspiration risks, and poor compliance.[1][2][3] These devices address acute and chronic breathing disorders, including hypoxia, hypercapnia, and COPD exacerbations, with over 4.5 million patients treated and 37,000+ units installed globally; the company reports $68.7M revenue and emphasizes clinical validation showing non-inferiority to non-invasive positive pressure ventilation (NiPPV) in preventing intubation.[1][4][6]
Vapotherm was founded in 1999 in Exeter, New Hampshire, by inventor Bill Nilon, who developed the first heated and humidified high-flow nasal cannula system in the late 1990s to enable non-invasive ventilation—delivering oxygen in and removing CO2 without masks.[1][3][5] Early challenges included a 2005 recall of the Vapotherm 2000i, followed by re-approval in 2006 and the 2009 launch of the Precision Flow flagship with integrated flow meter, blender, and oxygen analyzer.[3] Pivotal moments include FDA approval for expanded respiratory distress indications in 2018 (new QAV category/code), COVID-19 frontline use to avert mechanical ventilation, and innovations like the 2015 Q50 compressor and Heliox-compatible models.[3][4][5] The company went public (NYSE: VAPO) and has grown into a global player in 40+ countries.[2][6]
Vapotherm rides the wave of non-invasive respiratory care amid rising demand for comfortable, ventilator-sparing solutions, amplified by COVID-19's strain on ICUs and aging populations driving chronic conditions like COPD.[5][7] Timing aligns with post-pandemic focus on hospital efficiency, telehealth integration, and digital health; market forces include clinician shortages, ventilation backlogs, and preference for mask-free tech reducing care complexity.[2][4][6] It influences the ecosystem by pioneering HVT standards, fostering clinical research, and enabling AI-driven outcomes—lowering costs and improving quality of life for 4.5M+ patients while advancing biotech in respiratory devices.[1][6][7]
Vapotherm is poised for expansion through AI-enhanced digital solutions, global HVT adoption, and seasonal respiratory demand, building on COVID momentum and partnerships like Carnegie Mellon’s Vapotherm AI for Business program.[6][7][9] Trends like connected devices, ML for predictive care, and non-invasive shifts will shape growth, potentially evolving its influence via broader biotech integrations under parent Perceptive Advisors.[1][6] As the fastest-growing player in mask-free therapy, Vapotherm redefines respiratory support from distress to seamless recovery.[7]
Vapotherm has raised $73.0M in total across 3 funding rounds.
Vapotherm's investors include Brandon Capital Partners, Morgenthaler Ventures.
Vapotherm has raised $73.0M across 3 funding rounds. Most recently, it raised $20.0M Series C in July 2015.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2015 | $20.0M Series C | Brandon Capital Partners, Morgenthaler Ventures | |
| Apr 1, 2014 | $24.0M Series B | Brandon Capital Partners, Morgenthaler Ventures | |
| Apr 1, 2013 | $29.0M Series A | Brandon Capital Partners, Morgenthaler Ventures |